NeuroPace (NPCE) Competitors

NeuroPace (NASDAQ:NPCE) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.

Which has preferable valuation and earnings, NPCE or BVS?

NeuroPace has higher earnings, but lower revenue than Bioventus. NeuroPace is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$65.42M	5.54	-$32.96M	-$1.28	-10.77
Bioventus	$512.34M	0.71	-$156.23M	-$2.52	-1.82

Does the media favor NPCE or BVS?

In the previous week, NeuroPace had 5 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for NeuroPace and 6 mentions for Bioventus. NeuroPace's average media sentiment score of 0.45 beat Bioventus' score of -0.04 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in NPCE or BVS?

Bioventus received 2 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 59.52% of users gave Bioventus an outperform vote while only 54.76% of users gave NeuroPace an outperform vote.

Company	Underperform	Outperform
NeuroPace	Outperform Votes 23 54.76%	Underperform Votes 19 45.24%
Bioventus	Outperform Votes 25 59.52%	Underperform Votes 17 40.48%

Is NPCE or BVS more profitable?

Bioventus has a net margin of -30.49% compared to NeuroPace's net margin of -50.38%. Bioventus' return on equity of 2.25% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-50.38%	-153.76%	-31.73%
Bioventus	-30.49%	2.25%	0.62%

Which has more volatility & risk, NPCE or BVS?

NeuroPace has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Do analysts recommend NPCE or BVS?

NeuroPace currently has a consensus target price of $15.67, suggesting a potential upside of 13.86%. Bioventus has a consensus target price of $7.67, suggesting a potential upside of 67.03%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Bioventus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals believe in NPCE or BVS?

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 27.5% of NeuroPace shares are owned by company insiders. Comparatively, 29.1% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bioventus beats NeuroPace on 10 of the 18 factors compared between the two stocks.